Drug Trial Radar · NCT03066869
Efficacy and Safety of H.P. ACTHAR GEL in Adults With Retinal Vasculitis
Last checked: Nov 20, 2026Latest source record: Sep 12, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
40
Planned (sponsor's estimate)
Start
Mar 22, 2017
Primary completion
Feb 2020
Study completion Aug 2020
Sponsor
- Lead sponsor
- Ocular Immunology and Uveitis FoundationAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 1, 2017
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the short- and long-term efficacy and safety of Acthar for the treatment of adults with non-infectious retinal vasculitis.
Conditions
- Uveitis, Posterior
- Vasculitis Retinal
Interventions
H.P. ACTHAR GELDrug
H.P. Acthar Gel is an adrenocorticotropic hormone (ACTH) analogue indicated for ophthalmic diseases.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of responders to Acthar at the end of treatment.Time frame: 24 Weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Ocular Immunology & Uveitis Foundation
Waltham, Massachusetts · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.